ReviveMed Email Format
Biotechnology ResearchMassachusetts, United States2-10 Employees
ReviveMed is an MIT spinout AI-based metabolomics platform for precision medicine in oncology and cardiometabolic disease. Blood metabolites, e.g., glucose and cholesterol, are crucial direct readouts of drug response and have been associated with disease outcomes, yet under-explored, as <5% of them are characterized. Our patented AI platform characterizes 20 times more metabolites than current platforms, pioneering the development of blood-based metabolic tests of drug response and safety. The unprecedented amount of metabolomics data has enabled us, for the first time, to develop pre-trained foundation models for metabolomics to simulate treatment outcomes and pave the way for the future of precision medicine.